Alzheimer’s Therapeutics Market

The Alzheimer’s disease therapeutics market is projected to witness significant expansion, supported by the anticipated launch of multiple emerging therapies. Key late- and mid-stage candidates include BioVie’s Bezisterim (NE3107), AB Science’s Masitinib (AB1010), Annovis Bio’s Buntanetap, Cassava Sciences’ Simufilam (PTI-125), TauRx Therapeutics’ Hydromethylthionine mesylate (TRx0237), Novo Nordisk’s Semaglutide (NN6535), and Eli Lilly’s Remternetug (LY3372993), among others. In parallel, several novel agents in earlier stages of clinical development continue to strengthen the pipeline.

Stay ahead of emerging Alzheimer’s therapies: https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

The Alzheimer’s disease market is expected to grow steadily, fueled by the potential commercialization of multiple innovative therapies targeting diverse disease mechanisms. Alongside late-stage candidates, a robust early-stage pipeline is under development, highlighting continued investment and scientific momentum in the field.

DelveInsight’s Alzheimer’s Disease Market Insights report offers an in-depth analysis of current treatment paradigms, emerging therapies, individual drug market shares, and historical as well as forecasted market size from 2020 to 2034 across the 7MM, which includes the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways from the Alzheimer’s Disease Market Report

• According to DelveInsight’s assessment, the Alzheimer’s disease market size across the 7MM was approximately USD 5 billion in 2024.
• The United States represented the largest share, accounting for nearly 50% of the total 7MM market in 2024, compared with EU4 countries, the UK, and Japan.
• In 2024, there were an estimated 15 million diagnosed prevalent cases of Alzheimer’s disease and nearly 100 million prevalent cases of preclinical Alzheimer’s disease across the 7MM. These figures are projected to rise consistently through 2034, driven by population aging and enhanced diagnostic capabilities.
• DelveInsight estimates indicate that the US alone had around 5.5 million diagnosed prevalent cases of agitation associated with Alzheimer’s disease in 2024.
• A wide range of companies—including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Eisai, TauRx Therapeutics, Johnson & Johnson, and others—are actively advancing novel therapies expected to enter the Alzheimer’s disease market in the coming years.
• Prominent pipeline candidates include Masitinib (AB1010), Valiltramiprosate (ALZ-801), Mirodenafil (AR1001), Levetiracetam (AGB101), Blarcamesine (ANAVEX2-73), Buntanetap, Tricaprilin (CER0001), Bezisterim (NE3107), Semaglutide (NN6535), Remternetug (LY3372993), Masupirdine (SUVN-502), COBENFY (KarXT), IGC-AD1, T3D-959, LX 1001, AXS-05, ABvac40, E2814, HMTM/TRx0237, GV1001, ACI-35.030/JNJ-2056, LOMECEL-B, Pepinemab, SinaptiStim System, and others.

Alzheimer’s Disease Market Dynamics

The market dynamics for Alzheimer’s disease are expected to evolve substantially over the forecast period. Advances in structural and functional MRI, along with biomarker-driven diagnostics, have significantly improved insights into disease pathology. These developments have reinforced a diverse pipeline targeting amyloid deposition, tau pathology, neuroinflammation, and synaptic dysfunction, creating opportunities for innovative, cost-effective, and patient-friendly therapies.

The anticipated entry of therapies with improved efficacy profiles, combined with rising diagnosis rates, is expected to be a key driver of market growth across the 7MM. However, market expansion may be constrained by several challenges, including historically high clinical failure rates, complex disease biology, reliance on single-target strategies, and expensive diagnostic tools. Additionally, generic erosion of traditional drug classes, reimbursement hurdles, pricing pressures, workforce shortages, and persistent underdiagnosis may limit market uptake.

Explore DelveInsight’s complete Alzheimer’s Disease Market Insights report to uncover growth opportunities - https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

1. Eisai Co., Ltd. 

• Company & Country: Eisai Co., Ltd. (Japan)
• Drug Candidate: Lecanemab (marketed as LEQEMBI® / レケンビ®)
• Clinical Phase: Regulatory approval based on Phase III Clarity AD global trial data; launch/registration ongoing in Asia (including Korea).
• Mechanism of Action (MOA): Humanized monoclonal antibody binding amyloid-β (Aβ) protofibrils and fibrils, reducing brain Aβ deposits implicated in Alzheimer’s pathology.
• Latest Developments / Regulatory Updates:
  
  
• • LEQEMBI® was approved in South Korea in May 2024 for mild cognitive impairment due to AD and mild AD dementia, based on positive Phase III results demonstrating reduction in disease progression.
  • Subcutaneous formulation submission was filed with Japan’s PMDA (Nov 2025) to enable at-home dosing.
• Clinical Trial Registry IDs:
• • Clarity AD Phase III trial (global, including sites in Japan) data underpins approvals — typically: NCT03887455 (commonly cited for lecanemab; confirm via registry). (Note: specific Japan site entries can be found under that NCT number.)

2. Unaffiliated Platform Trial — jRCT2031250327

• jRCT ID: jRCT2031250327
• Phase: Phase III mult icenter randomized, double-blind, placebo-controlled platform study of trontinemab in early symptomatic AD (MCI to mild dementia) in Japan.
• Drug Candidate: Trontinemab
• MOA: Anti-amyloid/tau antibody (presumed; registry does not list full MOA)
• Company Sponsor: Listed under a clinical site/medical organization — not a Japanese pharmaceutical company. (Included here for visibility because it is a Phase III platform trial in Japan but not company sponsored.)

3. ADEL, Inc. 

• Company & Country: ADEL, Inc. (South Korea)
• Drug Candidate: ADEL-Y01
• Clinical Phase: Early-stage human trials (clinical stage presumed Phase I/II) as per news reports citing US early-stage human trials.
• Mechanism of Action (MOA): Monoclonal antibody targeting tau acetylation, a post-translational modification implicated in tau aggregation and neurodegeneration in Alzheimer’s disease.
• Latest Developments / Regulatory Updates:
• • In December 2025, ADEL signed a $1.04 billion development deal with Sanofi to co-develop and commercialize ADEL-Y01 globally, reflecting confidence in its differentiated MOA and early clinical data.
• Clinical Trial Registry IDs:
• • ADEL-sponsored clinical trial registrations could be present on clinicaltrials.gov or Korean registries but are not yet identifiable with unique IDs publicly linked to ADEL-Y01 as of the latest search.

Alzheimer’s Disease Treatment Market

Although Alzheimer’s disease remains incurable, early diagnosis and timely intervention play a crucial role in symptom management and quality-of-life improvement. Current therapies primarily focus on symptomatic relief by modulating neurotransmitter activity, including acetylcholine and glutamate pathways. For more than a decade, acetylcholinesterase inhibitors and memantine have served as standard options for symptomatic management.

Recent regulatory approvals have marked a shift toward disease-modifying approaches. In July 2023, the US FDA approved LEQEMBI (lecanemab) for early Alzheimer’s disease, followed by approvals in Japan and the UK. Subsequently, KISUNLA (donanemab) received FDA approval in July 2024, representing another major milestone in early-stage Alzheimer’s treatment.

Access in-depth insights on late-stage Alzheimer’s drug development and upcoming market launches now - https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Alzheimer’s Disease Pipeline Therapies and Key Companies

The Alzheimer’s disease pipeline continues to expand, with global players advancing innovative modalities. Notable candidates include BioVie’s Bezisterim, AB Science’s Masitinib, Annovis Bio’s Buntanetap, TauRx Therapeutics’ HMTM, Cassava Sciences’ Simufilam, Eli Lilly’s Remternetug, and Novo Nordisk’s Semaglutide, among others.

These therapies employ diverse mechanisms, such as anti-inflammatory pathways, neuroimmune modulation, translational inhibition of toxic proteins, and metabolic regulation, reflecting a shift toward multifaceted treatment strategies. Several of these agents are in Phase III development, with potential launches anticipated within the forecast horizon.

Recent Developments in the Alzheimer’s Disease Market